Skip to main content
UniHealth

Doctor search

Kristin N Anderson, MD

Medical Oncology · Greenbrae

NPI 1962732354

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
3
1 carrier
Office
1
Since medical school
17 years
University of Minnesota Medical School, 2009

Offices

1 location · Marin Cancer Care, Inc. · 13 clinicians in this group

Looking this up.

Hospitals listed: Marinhealth Medical Center · Novato Community Hospital · Sonoma Valley Hospital. That is not proof they admit you there this week.

Plans that list them

3 plans · 1 carrier

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Anderson’s office at (415) 925-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

Plans whose provider directory lists this clinician
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026

Hospitals they work in

3 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
  • Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend it
    Overall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
  • Sonoma Valley HospitalSonoma, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency departmentPatients rate it 4 of 5 · 79% would definitely recommend it
    Overall rating: 2 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for Marinhealth Medical Center

Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Marinhealth Medical Center
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.66 (3.59 to 7.73) · 1,505 casesWorseJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.177BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.85 (0 to 1.83) · 1,056 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.04 (0.72 to 1.36)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths167.34 (112.58 to 222.09) · 57 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.9 · 47 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths8.5 · 119 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.6 · 257 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths9.5 · 428 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths11.4 · 477 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.3 · 197 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.1 · 2,827 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.18 (0 to 0.38) · 6,990 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.41) · 6,838 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.41 (0 to 3) · 664 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.86 (1.4 to 4.33) · 1,436 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.38 (3.68 to 17.08) · 705 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.38 (0.72 to 8.04) · 672 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.66 (0.18 to 3.15) · 300 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.56 (0 to 1.25) · 5,550 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.4 · 76 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.396No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits13.1 · 275 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22 · 427 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits-20.3 · 289 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits3.3 · 494 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits-4.9 · 499 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits17.9 · 435 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.5 (3.6 to 8.4) · 93 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits11.2 (7.8 to 16) · 93 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.6 · 84 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.5 · 53 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.3 · 111 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13 (10.3 to 16.5) · 2,119 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1.1 (0.8 to 1.4) · 670 casesNo differentJan 2024 – Dec 2024

What patients said (1,233 patients answered, 19% of those asked)

Patient survey stars by topic at Marinhealth Medical Center
Cleanliness3
Nurse communication3
Doctor communication3
Communication about medicines2
Discharge information3
Overall hospital rating4
Quietness3
Recommend hospital4
Share of patients giving the best answer at Marinhealth Medical Center
Room was "always" clean68%
Nurses "always" communicated well73%
Doctors "always" communicated well74%
Staff "always" explained56%
Yes, staff "did" give patients this information85%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand71%
Doctors "always" listened carefully72%
Doctors "always" treated them with courtesy and respect80%
Patients who gave a rating of "9" or "10" (high)72%
Staff "always" explained new medications70%
Nurses "always" explained things so they could understand68%
Nurses "always" listened carefully68%
Nurses "always" treated them with courtesy and respect82%
"Always" quiet at night48%
"YES", patients would definitely recommend the hospital76%
Staff "always" explained possible side effects43%
Yes, staff "did" give patients information about possible symptoms85%
See every measure and the patient survey for Novato Community Hospital

Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Novato Community Hospital
Clostridium Difficile (C.Diff)Infections0BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1 (0 to 2.06) · 213 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.85 (0.4 to 1.3)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths8.2 · 25 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths10 · 111 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.1 · 140 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths11.3 · 42 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.8 · 627 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.2 (0 to 0.43) · 1,872 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.25 (0.04 to 0.46) · 1,796 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths2.92 (0.5 to 5.33) · 505 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.64 (0 to 3.36) · 317 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.2 (0.51 to 3.88) · 495 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths7.93 (0 to 17.29) · 323 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths4.88 (0.69 to 9.07) · 311 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.75 (0.22 to 3.27) · 96 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.41 (0 to 1.49) · 1,320 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.2 · 143 casesNoneApr 2023 – Mar 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.6 · 108 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-31.9 · 121 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits1.1 · 150 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.6 · 143 casesNoneJul 2023 – Jun 2025
Rate of readmission after hip/knee replacementUnplanned return visits5.4 · 118 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 27 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.5 (9.5 to 16.5) · 930 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.3) · 184 casesNo differentJan 2024 – Dec 2024

What patients said (334 patients answered, 30% of those asked)

Patient survey stars by topic at Novato Community Hospital
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital5
Share of patients giving the best answer at Novato Community Hospital
Room was "always" clean78%
Nurses "always" communicated well81%
Doctors "always" communicated well83%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand78%
Doctors "always" listened carefully84%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)82%
Staff "always" explained new medications77%
Nurses "always" explained things so they could understand76%
Nurses "always" listened carefully82%
Nurses "always" treated them with courtesy and respect86%
"Always" quiet at night54%
"YES", patients would definitely recommend the hospital84%
Staff "always" explained possible side effects49%
Yes, staff "did" give patients information about possible symptoms90%
See every measure and the patient survey for Sonoma Valley Hospital

Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 2 the same, 0 worse of 2 measures. Readmissions: 0 better, 6 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Sonoma Valley Hospital
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.11 (0.63 to 1.6)No differentJul 2022 – Jun 2024
Death rate for COPD patientsComplications and deaths8.2 · 37 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths11 · 41 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths16.6 · 106 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 35 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths5.6 · 345 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.21 (0 to 0.44) · 713 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.05 to 0.48) · 660 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.36 (0.77 to 5.94) · 101 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.65 (0 to 3.38) · 27 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.31 (0.58 to 4.03) · 100 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.86 (0 to 18.76) · 28 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.15 (0.84 to 9.45) · 27 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths1.12 (0 to 2.33) · 540 casesNo differentJul 2022 – Jun 2024
Clostridium Difficile (C.Diff)Infections0.651No differentOct 2024 – Sep 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits21.1 · 60 casesNoneJul 2023 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits15.5 · 47 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits7.1 · 100 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18 · 105 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 47 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits13.6 (10.2 to 17.9) · 486 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.6 to 1.3) · 83 casesNo differentJan 2024 – Dec 2024

What patients said (164 patients answered, 31% of those asked)

Patient survey stars by topic at Sonoma Valley Hospital
Cleanliness4
Nurse communication5
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness3
Recommend hospital4
Share of patients giving the best answer at Sonoma Valley Hospital
Room was "always" clean74%
Nurses "always" communicated well85%
Doctors "always" communicated well88%
Staff "always" explained65%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge88%
Doctors "always" explained things so they could understand84%
Doctors "always" listened carefully88%
Doctors "always" treated them with courtesy and respect92%
Patients who gave a rating of "9" or "10" (high)74%
Staff "always" explained new medications77%
Nurses "always" explained things so they could understand81%
Nurses "always" listened carefully82%
Nurses "always" treated them with courtesy and respect91%
"Always" quiet at night52%
"YES", patients would definitely recommend the hospital79%
Staff "always" explained possible side effects53%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$3,013,066

Medicare paid this office $3,013,066 for 388 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)83$44,489$154
Return visit (30+ min)228$44,385$103
Administration of chemotherapy into vein, 1 hour or less35$38,883$126
Short return visit (20+ min)100$7,732$72
Administration of additional new drug or substance into vein, 1 hour or less18$6,844$62
See all 18 services
Every Original Medicare service billed
Long return visit (40+ min)83$44,489$154
Return visit (30+ min)228$44,385$103
Administration of chemotherapy into vein, 1 hour or less35$38,883$126
Short return visit (20+ min)100$7,732$72
Administration of additional new drug or substance into vein, 1 hour or less18$6,844$62
New patient visit (60+ min)36$6,560$182
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)18$6,290$0
Injection of additional new drug or substance into vein30$4,216$14
Administration of chemotherapy into vein, each additional hour22$3,628$25
New patient visit (30+ min)39$3,580$92
Injection of drug or substance under skin or into muscle40$3,118$12
Initial hospital care with moderate level of medical decision making at least 75 minutes16$2,364$139
Injection of drug or substance into vein26$1,874$35
Injection, carboplatin, 50 mg11$1,235None
Infusion, normal saline solution , 1000 cc51$922None
Injection, palonosetron hcl, 25 mcg20$719None
Injection, dexamethasone sodium phosphate, 1 mg24$222None
Injection, diphenhydramine hcl, up to 50 mg18$40None

Procedures year by year

Procedures billed to Original Medicare by year
Procedure201920202021202220232024
Biopsy and aspiration of bone marrow sample for diagnosis14–––––

Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.

Who their Medicare patients are

388 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 15% · Women 64% · Also on Medicaid 11% · Health risk score 1.59. At or below the middle of the specialty; the typical medical oncology clinician is at 2.11.

Conditions among them: High blood pressure 62% · Cancer 48% · Coronary heart disease 24% · Chronic kidney disease 24% · Depression 21% · Atrial fibrillation 19% · Diabetes 16% · Heart failure 14% · Stroke 12% · COPD 11% · Dementia 4%.

The office billed $9,254,177, Medicare allowed $3,794,258 and paid $3,013,066; for 155,814 services of 87 kinds; $2,819,813 of it was for drugs given in the office and $193,253 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
2024388155,814771.59$9,254,177$3,013,066
2023393133,919771.65$7,303,252$2,322,823
2022438146,003761.65$8,018,602$2,571,750
2021409102,284761.71$5,880,215$1,859,916
2020358103,957761.85$5,125,142$1,641,744
201938275,740761.73$3,672,777$1,152,566
201835960,222761.86$3,057,697$953,265
201739170,078761.87$3,553,696$1,082,729
201645383,108762.00$2,683,098$815,471
20151139,235761.75$384,798$122,357

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 20 services

Original Medicare services billed in 2023
Return visit (30+ min)256$60,543$112
Administration of chemotherapy into vein, 1 hour or less38$31,167$134
Long return visit (40+ min)82$30,802$167
Injection, epoetin alfa, (for non-esrd use), 1000 units11$28,990None
Short return visit (20+ min)88$7,912$74
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)13$7,903$0
Administration of chemotherapy into vein, each additional hour23$4,853$28
Injection of additional new drug or substance into vein31$4,608$16
New patient visit (60+ min)22$4,478$204
Injection of drug or substance under skin or into muscle34$4,258$13
Administration of additional new drug or substance into vein, 1 hour or less15$4,254$66
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,004$148
New patient visit (45+ min)23$3,559$155
Injection of drug or substance into vein28$2,358$37
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes12$2,218$106
New patient visit (30+ min)24$2,061$86
Injection, palonosetron hcl, 25 mcg14$392None
Injection, dexamethasone sodium phosphate, 1 mg24$134None
Infusion, normal saline solution , 1000 cc14$104None
Injection, diphenhydramine hcl, up to 50 mg21$59None

2022: 26 services

Original Medicare services billed in 2022
Return visit (30+ min)241$60,216$120
Administration of chemotherapy into vein, 1 hour or less46$52,271$144
Short return visit (20+ min)238$28,879$75
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)19$22,001$1
Administration of chemotherapy into vein, each additional hour33$10,705$30
Long return visit (40+ min)33$8,834$170
Injection of additional new drug or substance into vein39$8,619$16
Administration of additional new drug or substance into vein, 1 hour or less21$7,396$70
New patient visit (60+ min)31$6,264$202
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise13$4,720$197
Injection of drug or substance under skin or into muscle41$3,376$14
Injection of drug or substance into vein33$3,341$38
Initial hospital care with moderate level of medical decision making at least 75 minutes17$3,207$178
New patient visit (45+ min)20$2,842$142
New patient visit (30+ min)24$2,182$91
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes13$1,941$92
Infusion into a vein for hydration, 31-60 minutes18$1,789$36
Short return visit60$1,705$27
Injection, zoledronic acid, 1 mg17$820None
Injection, palonosetron hcl, 25 mcg25$817None
Injection, carboplatin, 50 mg12$761None
Infusion, normal saline solution , 1000 cc47$569None
Injection, dexamethasone sodium phosphate, 1 mg36$268None
Injection, diphenhydramine hcl, up to 50 mg17$80None
Injection, ondansetron hydrochloride, per 1 mg16$67None
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise13$0$0

2021: 23 services

Original Medicare services billed in 2021
Injection, pembrolizumab, 1 mg11$312,871None
Short return visit (20+ min)283$48,342$74
Administration of chemotherapy into vein, 1 hour or less51$31,201$148
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)17$20,891$1
Injection, epoetin alfa, (for non-esrd use), 1000 units12$20,012None
Initial hospital care with moderate level of medical decision making at least 75 minutes41$7,298$178
Return visit (30+ min)36$5,370$107
Administration of additional new drug or substance into vein, 1 hour or less17$4,927$74
New patient visit (60+ min)24$4,626$193
Short return visit84$4,351$34
Injection of drug or substance into vein39$3,785$40
Injection of drug or substance under skin or into muscle41$3,378$13
New patient visit (45+ min)26$3,310$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes21$3,048$92
Injection of additional new drug or substance into vein38$2,298$17
New patient visit (30+ min)34$1,954$57
Injection, zoledronic acid, 1 mg27$1,804None
Administration of chemotherapy into vein, each additional hour14$1,445$31
Infusion, normal saline solution , 1000 cc93$1,434None
Injection, palonosetron hcl, 25 mcg16$662None
Injection, carboplatin, 50 mg11$362None
Injection, dexamethasone sodium phosphate, 1 mg26$195None
Injection, ondansetron hydrochloride, per 1 mg13$22None

2020: 22 services

Original Medicare services billed in 2020
Short return visit (20+ min)283$40,020$55
Injection, epoetin alfa, (for non-esrd use), 1000 units17$39,830None
Administration of chemotherapy into vein, 1 hour or less50$29,548$141
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)12$20,897$1
Return visit (30+ min)36$5,490$92
Initial hospital care with moderate level of medical decision making at least 75 minutes27$5,133$183
Administration of additional new drug or substance into vein, 1 hour or less15$4,832$70
Injection of drug or substance under skin or into muscle48$3,964$14
Injection of drug or substance into vein35$3,747$39
New patient visit (60+ min)18$2,991$166
Administration of chemotherapy into vein, each additional hour22$2,410$31
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes18$2,368$95
Injection of additional new drug or substance into vein35$2,160$16
Injection, zoledronic acid, 1 mg25$1,830None
New patient visit (45+ min)14$1,648$118
Short return visit42$1,583$30
Infusion, normal saline solution , 1000 cc92$1,324None
Injection, palonosetron hcl, 25 mcg18$1,006None
New patient visit (30+ min)14$959$68
Injection, dexamethasone sodium phosphate, 1 mg23$78None
Injection, ondansetron hydrochloride, per 1 mg13$23None
Injection, diphenhydramine hcl, up to 50 mg13$20None

2019: 27 services

Original Medicare services billed in 2019
Injection, pegfilgrastim, 6 mg14$141,543None
Short return visit (20+ min)285$45,109$62
Injection, epoetin alfa, (for non-esrd use), 1000 units15$28,470None
Administration of chemotherapy into vein, 1 hour or less53$24,880$138
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)11$14,140$1
Initial hospital care with moderate level of medical decision making at least 75 minutes43$7,843$178
Injection, palonosetron hcl, 25 mcg35$5,970None
New patient visit (60+ min)33$5,890$178
Administration of additional new drug or substance into vein, 1 hour or less24$4,990$68
Return visit (30+ min)36$4,580$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes27$4,214$92
Injection of drug or substance under skin or into muscle38$3,110$15
Injection of additional new drug or substance into vein46$2,970$16
New patient visit (30+ min)32$2,907$91
Administration of chemotherapy into vein, each additional hour27$2,845$30
Injection of drug or substance into vein31$2,486$36
Biopsy and aspiration of bone marrow sample for diagnosis14$2,268$162
Administration of additional new drug or substance into vein using push technique14$1,761$59
New patient visit (45+ min)11$1,501$136
Injection, zoledronic acid, 1 mg23$1,450None
Infusion, normal saline solution , 1000 cc87$1,121None
Short return visit22$896$34
Injection, carboplatin, 50 mg11$334None
Office for the evaluation and management of established patient that may not require presence of healthcare professional11$244$22
Injection, dexamethasone sodium phosphate, 1 mg40$168None
Injection, diphenhydramine hcl, up to 50 mg13$18None
Unclassified drugs11$14None

2018: 22 services

Original Medicare services billed in 2018
Short return visit (20+ min)277$43,508$62
Administration of chemotherapy into vein, 1 hour or less50$22,323$134
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)15$21,050$1
Injection, palonosetron hcl, 25 mcg20$5,264None
Initial hospital care with moderate level of medical decision making at least 75 minutes22$4,067$177
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes20$4,004$91
New patient visit (60+ min)20$3,355$168
New patient visit (30+ min)38$3,250$86
Injection of drug or substance into vein26$2,744$46
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less26$2,619$64
Injection of drug or substance under skin or into muscle24$2,279$18
Return visit (30+ min)18$2,161$98
Administration of additional new drug or substance into vein, 1 hour or less18$2,091$67
Administration of chemotherapy into vein, each additional hour19$2,079$30
Injection, zoledronic acid, 1 mg20$1,805None
Short return visit37$1,737$36
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less27$1,438$30
Infusion, normal saline solution , 1000 cc86$980None
Injection of additional new drug or substance into vein20$878$18
Injection, carboplatin, 50 mg11$299None
Injection, dexamethasone sodium phosphate, 1 mg28$70None
Injection, ondansetron hydrochloride, per 1 mg13$18None

2017: 26 services

Original Medicare services billed in 2017
Injection, rituximab, 100 mg13$130,104None
Short return visit (20+ min)287$44,564$61
Injection, epoetin alfa, (for non-esrd use), 1000 units15$37,663None
Administration of chemotherapy into vein, 1 hour or less52$29,104$134
New patient visit (60+ min)78$13,468$173
Return visit (30+ min)80$10,935$91
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)15$10,763$1
Initial hospital care with moderate level of medical decision making at least 75 minutes45$8,239$175
Injection, palonosetron hcl, 25 mcg24$7,920None
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes40$7,682$90
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less39$6,893$65
Injection of drug or substance under skin or into muscle40$4,755$24
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less47$4,164$30
Administration of additional new drug or substance into vein, 1 hour or less25$3,246$64
Administration of chemotherapy into vein, each additional hour31$3,081$27
Injection, zoledronic acid, 1 mg22$2,006None
Aspiration of bone marrow sample for diagnosis11$1,768$161
Biopsy of bone marrow15$1,604$107
Infusion, normal saline solution , 1000 cc83$990None
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion20$917$20
Injection, carboplatin, 50 mg11$783None
Short return visit20$764$38
Office for the evaluation and management of established patient that may not require presence of healthcare professional17$458$17
Injection, dexamethasone sodium phosphate, 1 mg39$139None
Injection, ondansetron hydrochloride, per 1 mg20$48None
Injection, diphenhydramine hcl, up to 50 mg18$21None

2016: 27 services

Original Medicare services billed in 2016
Injection, rituximab, 100 mg12$94,664None
Injection, epoetin alfa, (for non-esrd use), 1000 units13$90,589None
Short return visit (20+ min)277$44,033$60
Administration of chemotherapy into vein, 1 hour or less59$24,730$131
Return visit (30+ min)117$19,642$97
New patient visit (60+ min)83$14,685$177
Ct scan of abdomen and pelvis with contrast47$10,542$220
Injection, palonosetron hcl, 25 mcg28$9,536None
Injection of drug or substance under skin or into muscle33$6,605$24
Ct scan of chest with contrast58$6,205$107
Initial hospital care with moderate level of medical decision making at least 75 minutes32$5,953$175
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less54$5,642$29
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes36$5,215$90
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less21$3,284$63
Administration of additional new drug or substance into vein, 1 hour or less24$3,248$61
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes18$1,999$61
Long return visit (40+ min)13$1,952$122
Administration of chemotherapy into vein, each additional hour20$1,440$27
Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion26$1,413$20
Administration of additional new drug or substance into vein using push technique13$1,342$61
Infusion, normal saline solution , 1000 cc83$735None
Office for the evaluation and management of established patient that may not require presence of healthcare professional11$490$19
Short return visit11$336$31
Injection, dexamethasone sodium phosphate, 1 mg42$185None
Injection, ondansetron hydrochloride, per 1 mg22$51None
Injection, diphenhydramine hcl, up to 50 mg23$23None
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml72$7$0

2015: 9 services

Original Medicare services billed in 2015
Short return visit (20+ min)63$5,442$66
New patient visit (60+ min)25$4,612$184
Administration of chemotherapy into vein, 1 hour or less16$3,761$134
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,291$176
Return visit (30+ min)16$1,959$98
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes16$1,953$63
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less14$734$29
Infusion, normal saline solution , 1000 cc22$102None
Injection, dexamethasone sodium phosphate, 1 mg11$25None

Medicaid work

$602 in 2024

Medicaid paid $602 for 12 billed services this clinician did in 2024, up to 12 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Return visit (30+ min)12$602
Medicaid work by year
202412112$602
202399215$5,016
2022158223$5,802
2021132125$4,291
2020181126$4,229
201974116$2,711
201830115$1,332
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)83$3,747
Long return visit (40+ min)16$1,270

2022

Largest Medicaid services in 2022
Return visit (30+ min)72$2,983
Short return visit (20+ min)86$2,818

2021

Largest Medicaid services in 2021
Short return visit (20+ min)132$4,291

2020

Largest Medicaid services in 2020
Short return visit (20+ min)181$4,229

2019

Largest Medicaid services in 2019
Short return visit (20+ min)74$2,711

2018

Largest Medicaid services in 2018
Short return visit (20+ min)30$1,332

Drugs they prescribed that Part D paid

$3,442,773

Pharmacies billed $3,442,773 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

713 generic and 268 brand-name prescriptions · $3,442,773 in drug cost · 28 antibiotic prescriptions to 11 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Pomalyst35$755,625$21,589
Revlimid40$754,591$18,865
Jakafi14$244,045$17,432
Sprycel12$208,429$17,369
Xtandi12$172,173$14,348
See all 26 drugs
Every Part D drug this clinician prescribed
Pomalyst35$755,625$21,589
Revlimid40$754,591$18,865
Jakafi14$244,045$17,432
Sprycel12$208,429$17,369
Xtandi12$172,173$14,348
Tavalisse11$164,033$14,912
Kisqali12$136,249$11,354
Venclexta27$110,790$4,103
Eliquis49$31,989$653
Exemestane35$2,629$75
Letrozole105$2,387$23
Hydroxyurea72$2,091$29
Tamoxifen Citrate63$1,306$21
Acyclovir48$1,111$23
Dexamethasone42$815$19
Potassium Chloride28$458$16
Gabapentin27$413$15
Anastrozole18$341$19
Prochlorperazine Maleate31$326$11
Sulfamethoxazole-Trimethoprim21$274$13
Ondansetron30$261$9
Ondansetron Odt11$126$11
Prednisone13$115$9
Lorazepam23$115$5
Venlafaxine Hcl Er21$107$5
Amlodipine Besylate15$103$7

Year by year

Part D prescribing by year
2024981166None27%$3,442,773
2023903152NoneNone$2,568,981
20221,0181672% (16)None$3,126,064
20211,0231632% (18)27%$2,548,336
20201,0171505% (48)20%$1,641,133
20199281523% (26)None$1,355,467
20189551233% (26)24%$1,806,520
20179611225% (51)19%$1,155,371
20166441119% (60)21%$902,458
2015562523% (13)None$35,752

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 23 drugs

Part D drugs prescribed in 2023
Revlimid32$575,687$17,990
Pomalyst13$369,528$28,425
Lenalidomide25$349,001$13,960
Vonjo15$345,947$23,063
Jakafi13$237,231$18,249
Venclexta15$64,777$4,318
Eliquis63$42,603$676
Exemestane46$9,266$201
Letrozole101$2,962$29
Hydroxyurea79$2,510$32
Tamoxifen Citrate62$1,895$31
Acyclovir38$1,099$29
Venlafaxine Hcl Er24$977$41
Gabapentin42$714$17
Potassium Chloride21$417$20
Anastrozole22$330$15
Ondansetron22$283$13
Dexamethasone16$228$14
Sulfamethoxazole-Trimethoprim16$190$12
Sertraline11$154$14
Lorazepam19$142$7
Lisinopril13$55$4
Alendronate12$23$2

2022: 22 drugs

Part D drugs prescribed in 2022
Revlimid67$1,273,969$19,014
Jakafi28$485,827$17,351
Vonjo18$385,265$21,404
Pomalyst13$332,975$25,613
Eliquis80$49,756$622
Venclexta12$27,996$2,333
Exemestane44$8,599$195
Letrozole122$3,675$30
Hydroxyurea73$3,168$43
Tamoxifen Citrate71$2,043$29
Ondansetron32$1,125$35
Dexamethasone35$785$22
Acyclovir29$706$24
Venlafaxine Hcl Er33$659$20
Gabapentin32$618$19
Anastrozole12$295$25
Potassium Chloride30$290$10
Prochlorperazine Maleate27$266$10
Lorazepam39$162$4
Zolpidem16$111$7
Sulfamethoxazole-Trimethoprim14$88$6
Citalopram Hbr11$23$2

2021: 22 drugs

Part D drugs prescribed in 2021
Revlimid51$897,759$17,603
Jakafi49$712,622$14,543
Pomalyst11$233,340$21,213
Tavalisse13$157,834$12,141
Eliquis81$54,776$676
Venclexta12$27,560$2,297
Exemestane29$10,129$349
Letrozole132$5,785$44
Hydroxyurea74$3,991$54
Tamoxifen Citrate88$3,538$40
Venlafaxine Hcl Er32$1,060$33
Dexamethasone28$677$24
Acyclovir37$633$17
Gabapentin41$619$15
Potassium Chloride38$584$15
Anastrozole11$325$30
Prochlorperazine Maleate21$319$15
Ondansetron Odt11$276$25
Ondansetron16$264$16
Zolpidem15$196$13
Lorazepam37$192$5
Sulfamethoxazole-Trimethoprim13$39$3

2020: 24 drugs

Part D drugs prescribed in 2020
Revlimid46$777,425$16,901
Jakafi16$237,235$14,827
Tavalisse11$125,938$11,449
Eliquis65$37,487$577
Hydroxyurea72$5,004$69
Letrozole160$4,937$31
Tamoxifen Citrate94$4,514$48
Venlafaxine Hcl Er44$1,327$30
Potassium Chloride13$1,132$87
Dexamethasone41$1,060$26
Gabapentin34$581$17
Anastrozole22$560$25
Diphenoxylate-Atropine14$458$33
Hydrocodone-Acetaminophen19$416$22
Acyclovir23$311$14
Duloxetine12$274$23
Prochlorperazine Maleate19$271$14
Methadone17$239$14
Ondansetron12$238$20
Ondansetron Odt16$216$14
Lorazepam28$134$5
Zolpidem13$132$10
Prednisone13$127$10
Citalopram Hbr11$12$1

2019: 16 drugs

Part D drugs prescribed in 2019
Revlimid26$406,635$15,640
Iclusig18$321,982$17,888
Sprycel13$189,554$14,581
Eliquis55$30,867$561
Exemestane21$7,605$362
Hydroxyurea91$6,103$67
Tamoxifen Citrate111$5,357$48
Letrozole157$3,675$23
Venlafaxine Hcl Er56$1,243$22
Dexamethasone24$817$34
Acyclovir14$385$28
Hydrocodone-Acetaminophen11$384$35
Prochlorperazine Maleate23$262$11
Lorazepam40$182$5
Gabapentin12$163$14
Furosemide11$51$5

2018: 23 drugs

Part D drugs prescribed in 2018
Revlimid58$868,830$14,980
Iclusig12$213,495$17,791
Ibrance17$192,188$11,305
Sprycel12$158,929$13,244
Imbruvica19$143,518$7,554
Imatinib Mesylate23$100,617$4,375
Procrit18$55,312$3,073
Eliquis46$24,645$536
Xarelto12$8,265$689
Exemestane20$6,667$333
Hydroxyurea105$5,625$54
Tamoxifen Citrate95$3,457$36
Letrozole127$2,714$21
Dexamethasone29$453$16
Gabapentin21$358$17
Venlafaxine Hcl Er12$312$26
Ondansetron Odt12$212$18
Calcitriol11$177$16
Prednisone25$162$6
Lorazepam37$154$4
Acyclovir15$132$9
Pantoprazole12$109$9
Prochlorperazine Maleate14$58$4

2017: 24 drugs

Part D drugs prescribed in 2017
Revlimid26$330,859$12,725
Sprycel14$172,703$12,336
Imbruvica13$98,655$7,589
Imatinib Mesylate12$90,970$7,581
Procrit24$71,073$2,961
Eliquis35$13,350$381
Exemestane21$9,693$462
Hydroxyurea88$5,723$65
Letrozole141$2,615$19
Tamoxifen Citrate65$1,532$24
Valacyclovir16$405$25
Anastrozole18$330$18
Calcitriol11$312$28
Allopurinol14$305$22
Gabapentin30$305$10
Dexamethasone15$223$15
Sulfamethoxazole-Trimethoprim12$223$19
Venlafaxine20$210$11
Prednisone22$198$9
Lorazepam44$168$4
Ondansetron15$163$11
Escitalopram11$139$13
Prochlorperazine Maleate27$128$5
Alendronate17$67$4

2016: 23 drugs

Part D drugs prescribed in 2016
Revlimid19$210,305$11,069
Sprycel11$124,337$11,303
Imatinib Mesylate11$105,019$9,547
Imbruvica11$103,124$9,375
Procrit24$69,372$2,891
Oxycontin11$4,822$438
Hydroxyurea53$1,974$37
Letrozole62$1,399$23
Tamoxifen Citrate28$911$33
Valacyclovir14$533$38
Hydrocodone-Acetaminophen11$363$33
Zolpidem14$350$25
Anastrozole13$264$20
Gabapentin14$239$17
Calcitriol11$223$20
Prochlorperazine Maleate15$208$14
Dexamethasone15$187$12
Ondansetron11$186$17
Sulfamethoxazole-Trimethoprim11$150$14
Warfarin20$138$7
Levofloxacin11$130$12
Prednisone15$122$8
Lorazepam13$69$5

Money from drug and device companies

$115 in 2025

Industry payments by year
202547None$115
202435None$98
202322None$43
202124None$66
202012None$25
201922None$29

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
CelgeneReblozyl$69
4 payments
  • Meals for Reblozyl · 2025-08-19 · $18
  • Meals for Reblozyl · 2025-05-12 · $19
  • Meals for Reblozyl · 2025-03-19 · $16
  • Meals for Reblozyl · 2025-03-04 · $17
Boehringer Ingelheim PharmaceuticalsNone$16
1 payment
  • Meals · 2025-06-20 · $16
AbbvieImbruvica$16
1 payment
  • Meals for Imbruvica · 2025-12-03 · $16
Tempus AIXt Cdx$14
1 payment
  • Meals for Xt Cdx · 2025-10-29 · $14
See all 7 published payments
Every published payment
AbbvieMeals · 2025-12-03Imbruvica$16
Tempus AIMeals · 2025-10-29Xt Cdx$14
CelgeneMeals · 2025-08-19Reblozyl$18
Boehringer Ingelheim PharmaceuticalsMeals · 2025-06-20None$16
CelgeneMeals · 2025-05-12Reblozyl$19
CelgeneMeals · 2025-03-19Reblozyl$16
CelgeneMeals · 2025-03-04Reblozyl$17
See earlier years (2024, 2023, 2021, 2020, 2019)

2024: $98

Payments by company in 2024
CelgeneReblozyl$52
3 payments
  • Meals for Reblozyl · 2024-11-21 · $17
  • Meals for Reblozyl · 2024-06-07 · $17
  • Meals for Reblozyl · 2024-02-26 · $18
MedtronicOsteocool Rf Ablation System$35
1 payment
  • Meals for Osteocool Rf Ablation System · 2024-12-19 · $35
Merck Sharp & DohmeKeytruda$11
1 payment
  • Education for Keytruda · 2024-08-15 · $11

2023: $43

Payments by company in 2023
PfizerIbrance$25
1 payment
  • Education for Ibrance · 2023-09-22 · $25
CelgeneReblozyl$18
1 payment
  • Meals for Reblozyl · 2023-06-02 · $18

2021: $66

Payments by company in 2021
PfizerInlyta$54
3 payments
  • Education for Inlyta · 2021-12-01 · $26
  • Education for Lorbrena · 2021-11-03 · $16
  • Education for Inlyta · 2021-03-24 · $13
Gilead SciencesNone$12
1 payment
  • Education · 2021-06-01 · $12

2020: $25

Payments by company in 2020
PfizerXalkori$25
2 payments
  • Education for Lorbrena · 2020-02-24 · $11
  • Education for Xalkori · 2020-02-24 · $14

2019: $29

Payments by company in 2019
Boston ScientificWatchman$16
1 payment
  • Meals for Watchman · 2019-04-02 · $16
PfizerBraftovi$13
1 payment
  • Education for Braftovi · 2019-10-25 · $13

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2023Their institution$296,483
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2022Their institution$46,041
E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos Her2 Neg Neo Adjuvant · 2022Their institution$43,812
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2024Their institution$37,217
TOLMAR, INC. · Tol2506a · 2023Their institution$35,184
E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos Her2 Neg Neo Adjuvant · 2021Their institution$34,525
E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos Her2 Neg Neo Adjuvant · 2020Their institution$33,130
Eli Lilly and Company · Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2025Their institution$30,949
AstraZeneca UK Limited · Cambria-1 A Phase III, Open-Label,Randomised Study To Assess the Efficacy and Safety of Extended Therapy With Camizestrant (Azd9833, A Next Generation, Oral Selective Estrogen Receptor Degrader) Vs Standard Endocrine Therapy (Aromatase Inhibitor Or Tamoxifen) in Patients With Er+/Her2 · 2024Their institution$20,937
Tolmar, Inc. · Open-Label, Safety Extension Study for Subjects With Hormone-Receptor-Positive (Hr+), Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Breast Cancer Who Have Completed the Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (Ovelia) Study · 2024Their institution$20,192
AstraZeneca UK Limited · Cambria-1 A Phase III, Open-Label,Randomised Study To Assess the Efficacy and Safety of Extended Therapy With Camizestrant (Azd9833, A Next Generation, Oral Selective Estrogen Receptor Degrader) Vs Standard Endocrine Therapy (Aromatase Inhibitor Or Tamoxifen) in Patients With Er+/Her2 · 2025Their institution$20,060
Novartis Pharmaceuticals Corporation · Epik-B2: A Two Part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Alpelisib (Byl719) in Combination With Trastuzumab and Pertuzumab As Maintenance Therapy in Patients With Her2-Positive Advanced Breast Cancer With A Pik3ca Mutation · 2023Their institution$18,160
Genentech, Inc. · Phase III Study To Compare Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Mbc · 2025Their institution$17,500
Genentech, Inc. · Giredestrant Cdki of Choice in Esr1m Enriched 1l Hr Mbc Secondary Endocrine Resistant Patients · 2024Their institution$16,500
TOLMAR, INC. · Tol2506a · 2022Their institution$13,500
Tolmar, Inc. · A Phase 3, Single Arm, Openlabel Study Evaluating Ovarian Suppression Following Threemonth Leuprolide Acetate for Injectable Suspension (Tol2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormonereceptor Positive (Hr+), Human Epidermal Growth Factor Receptor 2 (Her2)Negative Breast Cancer · 2024Their institution$13,416
Merck Sharp & Dohme LLC · A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With Or Without Bevacizumab for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer Keynote-B96 , Engot-Ov65 · 2025Their institution$9,801
Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2023Their institution$9,271
TOLMAR, INC. · Tol2506a-Ext · 2025Their institution$8,973
E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos / Her2 Neg Neo Adjuvant · 2023Their institution$6,800
Tolmar, Inc. · A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate for Injectable Suspension (Tol2506) in Combination With Endocrine Therapy in Premenopausal Subjects With Hormone-Receptor–Positive (Hr+), Human Epidermal Growth Factor Receptor 2 (Her2)-Negative Breast Cancer · 2024Their institution$5,784
Becton, Dickinson and Company · 2022Their institution$4,385
TOLMAR, INC. · Tol2506a · 2025Their institution$4,044
Novartis Pharmaceuticals Corporation · Clinical Trial To Assess the Efficacy and Safety of An Alternative Dosing Regimen of Ribociclib in Breast Cancer · 2025Their institution$3,500
E.R. Squibb & Sons, L.L.C. · Phase III Study - Breast Cancer Hr Pos / Her2 Neg Neo Adjuvant · 2024Their institution$3,390
Eli Lilly and Company · Chemotherapy Induced Peripheral Neuropathy Natural History Study (Epiphany) · 2022Their institution$1,779
Eli Lilly and Company · Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2022Their institution$1,361
Janssen Research & Development, LLC · A Prospective Multinational Study of Real Life Current Standards of Care in Patients With Relapsed and/Or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Pi Imid and Cd38 Monoclonal Antibody Treatment · 2023Their institution$1,300
Eli Lilly and Company · Ember-3: A Randomized Open-Label Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy in Patients With Estrogen Receptor Positive Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2023Their institution$1,222
Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2025Their institution$673
Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2022Their institution$673
Eli Lilly and Company · Ember-3: A Randomized, Open-Label, Phase 3 Study of Ly3484356 Vs Investigator'S Choice of Endocrine Therapy, in Patients With Estrogen Receptor Positive, Her2 Negative Locally Advanced Or Metastatic Breast Cancer Previously Treated With Endocrine Therapy · 2024Their institution$81
Genentech, Inc. · Chemo Trastuzumab Vs Chemo Trastuzumab Pertuzumab · 2024Their institution$55

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
0.0 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1962732354
Trained
University of Minnesota Medical School, 2009 · 17 years ago
Gender
Female
More record details
Sole proprietor
Yes
Taxonomy
Student in a training program (390200000X)
Mailing address
3350 La Jolla Village Dr, San Diego, CA, 92161
NPI first listed
2010-01-06
NPI last updated
2010-01-06

This is when the NPI record was last certified, not a medical board exam.